Active substance
Naratriptan
- US FDA 10
- Health Canada 3
- US price lines 2
- NHS prices 2
- Safety 1
US FDA United States — FDA approvals (Drugs@FDA)
| Product | Strength | Form · route | Applicant | Status | First approved |
|---|---|---|---|---|---|
| NARATRIPTAN | EQ 1MG BASE; EQ 2.5MG BASE | tablet · oral | HIKMA PHARMS | Prescription | 7 Jul 2010 |
| NARATRIPTAN | EQ 1MG BASE; EQ 2.5MG BASE | tablet · oral | HERITAGE | Prescription | 28 Feb 2011 |
| NARATRIPTAN | EQ 1MG BASE; EQ 2.5MG BASE | tablet · oral | ORBION PHARMS | Prescription | 30 Apr 2012 |
| AMERGE | EQ 2.5MG BASE **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons**; EQ 1MG BASE **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons** | tablet · oral | GLAXOSMITHKLINE LLC | Discontinued | 10 Feb 1998 |
| NARATRIPTAN | EQ 1MG BASE; EQ 2.5MG BASE | tablet · oral | ANI PHARMS | Discontinued | 7 Jul 2010 |
| NARATRIPTAN | EQ 1MG BASE; EQ 2.5MG BASE | tablet · oral | CHARTWELL RX | Discontinued | 7 Jul 2010 |
| NARATRIPTAN | EQ 1MG BASE; EQ 2.5MG BASE | tablet · oral | PADAGIS US | Discontinued | 8 Jul 2010 |
| NARATRIPTAN | EQ 2.5MG BASE | tablet · oral | SUN PHARM INDS LTD | Discontinued | 14 Feb 2011 |
| NARATRIPTAN | EQ 1MG BASE; EQ 2.5MG BASE | tablet · oral | APOTEX CORP | Discontinued | 22 Apr 2011 |
| NARATRIPTAN | EQ 1MG BASE; EQ 2.5MG BASE | tablet · oral | AUROBINDO PHARMA USA | Discontinued | 31 May 2012 |
Canada Canada — marketed products (Health Canada)
| Brand | DIN | Strength | Form · route | Company |
|---|---|---|---|---|
| SANDOZ NARATRIPTAN | 02322323 | 2.5 MG | TABLET · ORAL | SANDOZ CANADA INCORPORATED |
| TEVA-NARATRIPTAN | 02314290 | 1 MG | TABLET · ORAL | TEVA CANADA LIMITED |
| TEVA-NARATRIPTAN | 02314304 | 2.5 MG | TABLET · ORAL | TEVA CANADA LIMITED |
Prices — United States and England
| Source | Product as listed | Price | Unit / pack | Date |
|---|---|---|---|---|
| US NADAC | NARATRIPTAN HCL 1 MG TABLET | $1.77638 | per EA | 23 Sep 2026 |
| US NADAC | NARATRIPTAN HCL 2.5 MG TABLET | $1.08353 | per EA | 23 Sep 2026 |
| NHS Drug Tariff | Naratriptan 2.5mg tablets | £1.44 | 6 tablet | 1 Oct 2026 |
| NHS Drug Tariff | Naratriptan 2.5mg tablets | £2.88 | 12 tablet | 1 Oct 2026 |
NADAC: average price US retail pharmacies pay to buy the medicine. NHS Drug Tariff Part VIIIA: basic price reimbursed to pharmacies in England and Wales.
Safety signals and safety-related labeling changes
- US FDA 29 Nov 2016 AMERGE — safety-related labeling change
Labeling sections changed: Use in Specific Populations; Patient Counseling Information / Patient Information / Medication Guide
Values as published by each source: SFDA human drug list (4-2026, as published by the Council of Health Insurance; indications from the CHI Daman Drug Formulary), Drugs@FDA, EMA medicines data, Health Canada Drug Product Database (Open Government Licence – Canada), CMS NADAC, NHS Drug Tariff Part VIIIA (NHSBSA Copyright, Open Government Licence v3.0), WHO Model List of Essential Medicines (CC BY 3.0 IGO; regrouped by active substance, not created by WHO), EMA PRAC, US FDA safety-related labeling changes and MHRA Drug Safety Update (Open Government Licence v3.0). Sources and reuse. Not a substitute for the official registers or the product information.